We thank Eric Giannoni and colleagues and Giancarlo Ceccarelli and colleagues for their comments on our Correspondence.[@bib1] New data have since highlighted that patients with COVID-19 have an altered gut microbiome with depletion of beneficial commensals (*Eubacterium ventriosum, Faecalibacterium prausnitzii, Roseburia* and *Lachnospiraceae* taxa) and enrichment of opportunistic pathogens (*Clostridium hathewayi, Actinomyces viscosus, Bacteroides nordii*) during hospitalisation.[@bib2] Importantly, gut microbiome configuration was associated with COVID-19 disease severity, and altered gut microbiota persisted even after clearance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), suggesting that the virus might inflict prolonged harm to human microbiome homoeostasis.[@bib2] Other risk factors for severe COVID-19, including old age, obesity, and diabetes mellitus,[@bib3] have been shown to be associated with gut dysbiosis, which might contribute to the poor prognosis of COVID-19.[@bib4]

During this crucial moment, with more than 6 million confirmed cases of COVID-19 globally, we understand that the situation is desperate, and it is not uncommon to try all alternative measures. In the absence of a vaccine or effective therapy for COVID-19, we agree that probiotics represent a complementary approach for the prevention and restoration of SARS-CoV-2-induced mucosal damage or inflammation through the modulation of gut microbiota. Probiotics exert their beneficial effects through several different mechanisms, and substantial differences appear to exist between different probiotic bacterial species and strains. Organisms therefore need to be selected in a rational manner to treat different diseases.[@bib5] Currently, questions remain concerning which patients should receive probiotics, what is the best way to deliver probiotics, how to ensure optimal delivery, and whether there is variation in efficacy among different populations. As the world waits in semi-lockdown mode, continued scientific progress for COVID-19 prevention or treatment is highly important, and probiotics represent one option. We call for robust and well planned studies that can facilitate the identification of probiotic strains, including both well documented probiotics and novel COVID-19-specific probiotics, that might result in reduced susceptibility to COVID-19 or less severe disease.
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